Abstract Details
|
Robert A. Bermel, MD, FAAN
(Cleveland Clinic)
PRESENTER |
Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Bermel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Bermel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Bermel has received research support from Biogen. The institution of Dr. Bermel has received research support from Roche. The institution of Dr. Bermel has received research support from Novartis. Dr. Bermel has received intellectual property interests from a discovery or technology relating to health care. |
| Parul Houston | No disclosure on file |
| Ron Hashmonay, MD | No disclosure on file |
| Xiangyi Meng, PhD (Novartis) | Dr. Meng has nothing to disclose. |
| Sebastian F. Von Rosenstiel, MD, PhD (Takeda) | Dr. Von Rosenstiel has received personal compensation for serving as an employee of Takeda. Dr. Von Rosenstiel has stock in Takeda. |
| Nicolaos Sfikas (Novartis Pharma AG) | No disclosure on file |
| Simrat Randhawa, MD (Novartis Pharmaceuticals Corporation) | No disclosure on file |
| Daniel Kantor, MD, FAAN (Medical Partnership 4 MS+) | Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to AAN interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to AAN interests or activities. |